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Vascular perfusion and hypoxic areas in RIF-1 tumours after photodynamic
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Summary The influence of photodynamic therapy (PDT) on vascular perfusion and the development of
hypoxia was investigated in the murine RIF-I tumour. Image analysis was used to quantify changes in
perfusion and hypoxia at 5 min after interstitial Photofrin-mediated PDT. The fluorescent stain Hoechst 33342
was used as an in vivo marker of functional vascular perfusion and the antibody anti-collagen type IV as a
marker of the tumour vasculature. The percentage of total tumour vasculature that was perfused decreased to
less than 30% of control values after PDT. For the lower light doses this decrease was more pronounced in the
centre of the tumour. The observed reduction in vascular perfusion showed a good linear correlation (r =0.98)
with previously published tumour perfusion data obtained with the 86Rb extraction technique. The image
analysis technique provides extra information concerning the localisation of (non)-perfused vessels. To detect
hypoxic tumour areas in vivo, an immunohistochemical method was used employing NITP [7-(4'-(2-
nitroimidazol-l-yl)-butyl)-theophylline]. A large increase in hypoxic areas was found for PDT-treated tumours.
More than half the total tumour area was hypoxic after PDT, compared with <4% for control tumours. Our
studies illustrate the potential of image analysis systems for monitoring the functional consequences of PDT-
mediated vascular damage early after treatment. This provides direct confirmation that the perfusion changes
lead to tissue hypoxia, which has implications for the combined treatment of PDT with bioreductive drugs.
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The three-dimensional growth of solid tumours requires a
vascular network of new capillaries. These new capillaries
lack a supporting architecture and are thin-walled and leaky.
The lack of a smooth muscle wall also renders them less
responsive to vasoactive stimuli and more prone to
compression, especially in larger tumours in which the
interstitial pressure is raised. Thus, a tumour often has
oxygen diffusion gradients and a relatively poor nutrient
supply, which may result in areas of necrosis (Trotter et al.,
1989; Vaupel et al., 1989; Folkman, 1993). There is a close
relationship between the width of the viable cell rim around
the vessels and the distance that oxygen diffuses through the
tumour. In certain tumour types, small areas of necrosis are
seen between the blood vessels, i.e. a corded tumour structure
(Thomlinson and Gray, 1955). Central necrosis is also a
common feature of larger tumours. Cells under extremely low
Po2 values are likely to exist close to the areas of necrosis.
These areas of chronic hypoxia are the result of oxygen
diffusion limitations. Transient, acute hypoxia has also been
demonstrated in tumours (Trotter et al., 1989). This is a
perfusion-limited lypoxia that is caused by a temporary
interruption of blood flow within the vasculature as the
vessels undergo spontaneous opening and closing. Both
chronic and acute mechanisms are responsible for the
presence of hypoxic cells in tumours (Chaplin et al., 1987).
The percentage of hypoxic cells in a tumour may alter
during therapy as previously hypoxic cells reoxygenate or
new areas become hypoxic. Simple, rapid tests for the
presence of hypoxic cells in tumours (e.g. Hirsch et al.,
1987; Hodgkiss et al., 1991) could enable therapies like
radiotherapy and photodynamic therapy (PDT) to be
optimised on the basis of the oxygen status of the tumours.
The hypoxic marker NITP [7-(4'-(2-nitroimidazol-1-yl)-butyl)-
theophylline] (Hodgkiss et al., 1991) detects the presence of
severely hypoxic cells, since nitroimidazoles are reduced in
vitro at low oxygen levels, with K values of 0.02-0.2%
oxygen (oxygen level required for half-maximum sensitivity)
depending on cell line and compound (Taylor and Rauth,
1982; Mulcahy, 1984; Hodgkiss et al., 1991). Hypoxia
represents a potential disadvantage to tumour cell killing by
PDT, since fully hypoxic cells are completely resistant to this
treatment; K values of 0.5 1-% oxygen have been determined
for PDT cell killing in vitro (Henderson and Fingar, 1987;
Chapman et al., 1991a). Consequently even if all the
oxygenated cells of a tumour are killed by PDT, a hypoxic
subpopulation could survive and allow the tumour to regrow.
Severe PDT-induced vascular damage, which results in
oxygen and nutrient deprivation, does, however, lead to
secondary tumour cell death of these hypoxic cells
(Henderson et al., 1985). An understanding of the oxygen
status of the tumour before and after PDT is very important
for optimising treatment schedules, particularly if PDT is to
be combined with bioreductive drugs. Intervention with
bioreductive drugs could potentially increase the killing of
naturally occurring hypoxic tumour cells or cells rendered
hypoxic by PDT (Gonzalez et al., 1986; Bremner et al., 1992;
Baas et al., 1994). Hypoxia can occur even before the
development of PDT-induced vascular damage. The photo-
chemical processes involved in PDT consume oxygen very
rapidly and oxygen depletion can occur during continuous
illumination, particularly at high fluence rates (Foster et al.,
1991).
The purpose of this study was to analyse the patterns of
vascularisation and hypoxic areas simultaneously in the RIF-
1 tumour before and after PDT and to examine the influence
of PDT on vascular perfusion and oxygen status in the
tumour. The morphology of the vasculature was visualised
with an antibody directed against the basal lamina of the
blood vessels and areas of functional perfusion were
identified with Hoechst 33342. For identifying the hypoxic
areas in the tumour, the immunologically detectable
hapten theophylline was used, covalently bound to a 2-
nitroimidazole (NITP).
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Materials and methods
Animal models
All experiments were carried out in accordance with
protocols approved by the local experimental animal welfare
committee and conformed to national and European
regulations for animal experimentation. Female C3H/Km
mice were used, weighing 21 -30 g at an age of 11- 16 weeks.
Approximately 1 x 105 RIF-1 cells [maintained and passaged
according to recommended in vivo/in vitro protocols described
by Twentyman et al. (1980)] were inoculated subcutaneously
on the lower dorsum of mice, which were briefly
anaesthetised with enflurane. Tumour growth was documen-
ted three times per week by calliper measurements in three
orthogonal diameters. PDT treatment was given 11-15 days
(mean 12.2+0.4 s.e.) after inoculation, when the tumour had
reached a mean diameter of 5-6 mm. The tumours were free
of evident necrosis at these sizes.
Interstitial photodynamic therapy of tumours
The mice were injected i.p. with Photofrin (supplied by
Quadra Logic Technologies, Vancouver, Canada). Photofrin
was dissolved in 5% dextrose at a concentration of
2 mg ml '(for a dose of 10 mg kg-'). The photosensitiser
was injected 1 day before illumination. This time interval was
based on previous studies to establish times of maximum
drug uptake and photosensitisation (van Geel et al., 1995a).
The light source was a dye laser (Spectra Physics model
373) pumped by a 12 W argon laser (Spectra Physics model
171). DCM [(4-dicyanomethylene)-2-methyl-6-(p-dimethami-
no)-4H-pyrane: Radient Dyes Chemie, Wermelkirchen,
Germany] was used as the dye to obtain red laser light of
628+3 nm (mono Chromator Oriel model 77320). The light
was directed to a beam splitter that divided the light equally
among four outputs, to which non-scintillating polystyrene
fibres (Bicron BCF, 1 mm outer diameter) with 1 cm
cylindrical diffusing tips were attached. The output from
each fibre was adjusted to 100 mW cm-' and energies of 30-
200 J cm-' were delivered by varying the exposure time from
5 to 34 min. The diffusing fibres were inserted through the
centre of the tumours of unanaesthetised mice held in
restraining jigs, as described by Baas et al. (1993). Mice
were kept in subdued light after receiving the photosensitiser.
86RbCl extraction of estimates of vascular perfusion
Vascular perfusion relative to the cardiac output was
measured using the 86RbCI extraction technique as described
previously (van Geel et al., 1994). These results have been
previously reported but are included here for comparison
with the image analysis estimates of perfusion.
Staining ofperfused vessels
The perfusion marker Hoechst 33342 (Aldrich, Milwaukee,
WI, USA) was dissolved in sterile saline immediately before
use. Mice were injected i.v. via one of the lateral tail veins
with 0.1 ml Hoechst (at a concentration of 9 mg ml-') 5 min
after illumination. Mice were killed by cervical dislocation
1 min after injection to prevent diffusion of Hoechst 33342
into adjacent non-perfused vascular structures. Thus, Hoechst
specifically labels the nuclei of endothelial cells and nuclei of
the cells adjacent to the vessel walls, thereby delineating the
perfused vessels. The tumours were excised and frozen in
liquid nitrogen before storing at -70°C until they were
sectioned. Frozen sections were taken from three levels
(periphery, centre and contralateral periphery; three sections
each) of each tumour.
As a marker of the basal lamina of the tumour
microvasculature, an antibody against the basal lamina
component collagen IV was used (rabbit polyclonal antibody
against collagen type IV, Eurodiagnostics BV, Oss, The
Netherlands) as described by Bernsen et al. (1995). Briefly,
sections were air dried and fixed in acetone for 10 min.
Subsequently they were washed in phosphate-buffered saline
(PBS) for 10 min. Sections were incubated with the antibody
to collagen IV (1: 50 dilution in PBS containing 10% normal
goat serum) for 45 min. After washing in PBS, the second
antibody (goat anti-rabbit TRITC conjugated: Tago,
Burlingame, USA) was applied at a dilution of 1: 25 in
PBS containing 10% normal goat serum. The vascular
pattern of RIF-I tumours was visualised with a fluorescence
microscope (Axioshop, Zeiss) with 510-560 nm excitation
and 590 nm emission filters showing red fluorescence.
Hoechst 33342 could be studied under ultraviolet illumina-
tion showing blue fluorescence (excitation at 365 nm and
emission at 420 nm) in the same sections.
Staining of hypoxic areas
The hypoxic marker NITP (supplied by Dr Hodgkiss) was
dissolved in peanut oil (Sigma, St Louis, MO, USA)
containing 10% dimethyl sulphoxide (DMSO) and injected
i.p. in a volume of 0.27 ml for a 25 g mouse (0.5 mmol kg-').
Animals were injected 30 min before illumination and killed
by cervical dislocation 120 min after administration of the
drug. At this time, immunohistochemical detection of the
bound theophylline groups in mouse tumours has been
shown to be optimal (Hodgkiss et al., 1991). Previous results
had demonstrated no significant difference in vascular
perfusion determined (by 86Rb extraction) at 5 min or 2 h
after PDT of RIF-I tumours (van Geel et al., 1994). Freshly
excised tumours were frozen immediately in liquid nitrogen
and stored at -70°C until they were sectioned. The method
described by Hodgkiss et al. (1991), with minor modifica-
tions, was used to stain hypoxic areas. Frozen sections were
air dried and fixed in cold acetone. Non-specific sites were
blocked with 0.5% normal goat serum in PBS. A rabbit anti-
theophylline antibody (Sigma), diluted 1: 2 in PBS, was
applied and the sections incubated for 1 h. Pilot studies
indicated that the best results were obtained with this
dilution. After washing in PBS the sections were incubated
for 1 h with a second biotinylated antibody (1:100).
Subsequently, avidin alkaline phosphatase (Sigma) was
added and the sections were incubated for 45 min. After
final washings with PBS the enzyme substrate (containing
0.04% 4-nitro-blue tetrazolium chloridie +0.02% 5-bromo-4-
chloro-3-indolyl phosphate +0.8% dimethylformamide in
0.1 mM Tris/HCl buffer pH 9.5+50 mM magnesium chlor-
ide + 0.1 M sodium chloride) was added, resulting in a red
purple staining of the hypoxic areas (Coco Martin et al.,
1992).
Image analysis
Whole tumour sections were automatically scanned using a
digital image processing system to quantitate tumour vascular
area and percentage of perfused vessels (after staining of
sections for collagen and in vivo Hoechst injection respec-
tively). The digital imaging procedure is described in detail by
Rijken et al. (1995). Briefly, the tumour sections were scanned
twice on the computer-controlled motorised stage (Marz-
hauzer, Wetzlar, Germany) of a fluorescence microscope
(Zeiss, Oberkochen, Germany), using two different filters
(Hoechst and TRITC detection) and an intensified solid state
camera (MXRi: HCS, Eindhoven, The Netherlands). Major
artifacts such as air bubbles and mechanically damaged areas
were excluded from analysis. Each image was processed to
detect the stained structures using the following processing
operations: image reduction, shading correction, object
isolation from the background using a previously determined
threshold. Per tumour section, new threshold values could be
determined interactively before scanning the section if
intensity differences between sections occurred. After proces-
sing all fields of each scan (field size; 1.22 mm2, 10 x
objective: digital imaging application TCL-image, TNO,
Delft, The Netherlands) the scanned area was reconstructed
into one large image. This resulted in two composite images,
one with vascular structures (as stained with TRITC; Figure
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sections), Hoechst 33342 was injected 150 min after NITP
and the mice were sacrificed 1 min after Hoechst 33342
injection. After staining for hypoxia, clear red purple areas
were detected under the light microscope. The whole tumour
sections were then scanned, using a charged-coupled device
(CCD) camera (MX-5, HCS, Eindhoven, The Netherlands), a
light microscope (Zeiss) and the same staged-coupled
computer system with digitial imaging application as
described earlier, for quantitative analysis of hypoxic areas.
Again, the scanned area was reconstructed into one large
image. The relative hypoxic area (RHA) was expressed as the
total surface of the hypoxic areas divided by the total tumour
surface. For illustration of the spatial relationship between
hypoxic and perfused areas, the image of perfused vessels
stained by Hoechst in adjacent tumour sections was merged
with the image of hypoxic areas. The perfused vessels stained
blue and hypoxic areas were given a pseudocolour green.
Figure 1 Black and white illustrations of the combination of
composite images, obtained after scanning tumour sections of the
RIF-1 tumour using a semiautomated image analysis system, to
analyse vasculature and perfused vessels in the same tumour
section. (a) First scan of vasculature (stained with anti-collagen
IV). (b) Second scan of perfused vessels (Hoechst). (c) Overlap of
(a) and (b) to indicate the vascular structures that were perfused.
la) and another with the perfused areas (Hoechst; Figure lb).
The relative vascular area (RVA) is defined as the total
surface of all vascular structures divided by the total tumour
area. When the two composite images were combined, the
overlapping stained vessels represented the vasculature, which
was perfused by Hoechst 33342 at the time of injection
(Figure lc). The area of the overlapping vasculature divided
by the total vascular area yielded the perfused fraction (PF)
in this tumour section. The relative perfused tumour area
(RPTA) was determined by dividing the perfused vascular
area by the tumour area.
To compare spatial distribution of perfused vessels with
measurement of hypoxic areas in the same tumour (adjacent
Statistical analysis
The means and standard errors (s.e.) were calculated for three
sections ofeach of the central and/or peripheral areas of each
tumour (n=2-4) and used for further statistical analysis.
The significance of difference in vascular parameters or the
level of hypoxia for the control and treated groups was




The mean relative vascular area (RVA) as determined by
image analysis varied from 4 to 12% for control (untreated,
Photofrin or light alone) and treated tumours (see Table I).
Within the same tumour the mean RVA was generally fairly
homogeneous through the central and peripheral part of the
tumour (Figure 2a and b), although the periphery was
slightly, but not significantly, better vascularised than the
centre of the tumour after light alone. No significant
difference was found between the mean RVA of the
untreated control group and all the other groups (drug
alone, light alone or PDT).
The mean relative perfused total area (RPTA) of untreated
control tumours was 3.0+ 1.1%. There was a reduction after
Photofrin or light alone (2.2+0.3% and 1.5% +0.2%
respectively) which was most marked in central areas of
tumours treated with light alone, probably caused by fibre
insertion (Table I). The 86Rb extraction technique (separate
tumours) also demonstrated a small, but significant decrease
in blood flow of tumours treated with fibre or light alone
(van Geel et al., 1994). PDT with 200 J cm-' caused a further
reduction in relative perfused tumour area to 0.7+0.3%; the
perfusion fraction (PF) in these tumours was homogeneous
throughout the whole tumour. Previous studies had
demonstrated that Photofrin-mediated PDT with
200 J cm-' resulted in a tumour regrowth time (to 2 mm
larger than treatment size) of 16.0+0.9 days compared to
2.8+0.1 days for untreated controls; no cures were found
with this light dose (van Geel et al., 1995a,b). Tumours
treated with PDT at lower light doses (30-60 J cm-') also
had reduced RPTA, which was most evident in the central
parts of the tumour (Figure 2b). After these lower light doses
the tumours all regrew in less than 8 days (van Geel et al.,
1995b).
PDT caused a dose-dependent reduction in tumour
perfusion (Figure 3), as assessed by image analysis. The PF
of the RIF-l tumour decreased significantly from 34.5+9.7%
in untreated tumours to 10.8+2.5% at 5 min after
200 J cm-'. These vascular perfusion data showed a good
linear correlation (r=0.98) with tumour perfusion previously
estimated by the 86Rb extraction technique (van Geel et al.,
1994) (Figure 4).Tumour hypoxia after PDT
IPJ van Geel et al
Table I Vascular and hypoxic parameters of the RIF-1 tumour
Treatment Tumour RVA (%) RPTA (Oo) PF (O) RHA (Oo)
Untreated control c 8.5±3.4 2.8±0.8 35.0±7.0 3.6±0.01
p 12.2±3.9 3.9± 1.1 34.2± 14.9 3.5±0.4
t 9.4±4.1 3.0± 1.1 34.5±9.7 3.5±0.2
Photofrin alone (10 mg kg ') c 5.9+ 1.0 2.1 +0.2 35.3±8.8 3.2± 1.1
p 6.8 ±0.1 2.3 ±0.4 35.4±9.6 2.1 ±0.6
t 6.3 ± 0.5 2.2 ± 0.3 36.6 ± 8.4 2.5 ± 0.7
Light alone (200 J cm ) c 3.9 ±0.4 0.7 ±0.6 20.8± 17.1 3.0± 1.4
p 7.4±2.4 2.3± 1.0 30.2±4.1 5.3±3.4
t 5.6± 1.4 1.5±0.2 25.5 ±6.5 4.5 ±2.8
Photofrin-PDT (200 J cm c 6.3 ±3.5 0.5 ±0.4 8.3± 1.6 45.1 ± 1.5
p 6.6±0.7 0.9±0.3 13.2±3.4 53.9±2.5
t 6.4±2.1 0.7±0.3 10.8±2.5a 51.0±2.1a
RVA, relative vascular area; RPTA, relative perfused total area; PF, perfusion fraction; RHA, relative hypoxic area; c, central part ofthe tumour;
p, peripheral tumour; t, centre +periphery. aThe whole-tumour data differ significantly (P <0.05) from the untreated control group. Values are
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Figure 3 Effect of PDT on the vascular perfusion (0) and
hypoxia (0) of a 5mm diameter RIF-1 tumour 5min after
illumination with different light doses given at 24h after
10mgkg Photofrin as determined with image analysis. Control
values (shown at 0Jcm- ' light dose) represent untreated tumour
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Figure 2 Vascular perfusion in a 5 mm RIF-1 tumour. The vessel
area is shown in red and the perfused tumour area in blue for (a)
control tumour (b) experimental tumour (30 J cm- '). The overlap
of the vessel and perfused tumour area is shown in pink; this
indicates the vessels that were perfused.
Hypoxic areas
The relative hypoxic area (RHA) (acute and chronic),
including the necrotic areas was quantified by image
analysis. Alkaline phosphatase visualisation of the theophyl-
line tag in frozen sections of the control tumours showed a
very low background staining of unbound metabolites of
NITP (Figure 5a; Table I). The RHA in a 5 mm untreated
RIF-l tumour was 3.5+0.2%. No significant difference was
Figure 4 Correlation between vascular perfusion measured 5min
after PDT by the image technique and g6Rb technique (van Geel
et al., 1994). The correlation coefficient between the two
techniques is 0.98.
found between the control groups but PDT clearly increased
the hypoxic fraction (Figure 5b; Table I). There was a light
dose-dependent increase in hypoxic areas at 5 min after PDT,
with a corresponding dose-related decrease in vascular
perfusion (Figure 3). Superimposed images of adjacent
tumour sections stained for hypoxic and perfused areas
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Figure 5 Perfused and hypoxic areas in a 5 mm RIF- 1 tumour.
Again the perfused vessels are given in blue and the hypoxic areas
in (pseudocolour) green for (a) control tumour (b) experimental
tumour (30 Jcm -)
Discussion
This study indicates that subcurative interstitial PDT doses
markedly decreased vascular perfusion in the centre and
periphery of the RIF-1 tumour. For the lower light doses this
decrease was more pronounced in the centre of the tumour
close to the light source. Decreased perfusion resulted in a
light dose-related increase in hypoxic areas, especially in the
central part of the tumour.
There are still problems associated with estimating the
oxygenation status of individual tumours and their hypoxic
fractions, e.g. invasiveness of the technique or large
variability of signals measured in tumours from different
animals. Correlations between results of two or more assays,
as presented in this study, lend weight to the conclusions
derived from such studies.
PDT-mediated cell kill with drugs such as Photofrin
requires the presence of molecular oxygen and therefore an
intact blood flow. Several studies with animal tumours
(Henderson et al., 1985; Star et al., 1986; Chapman et al.,
1991b) suggest that vascular elements are the most sensitive
targets to PDT and that secondary tumour cell death is
induced by vascular shutdown. Most of these studies have
focused on determination of total tumour blood flow and less
attention has been paid to quantitative visualisation and
localisation of functional perfusion and hypoxic areas
simultaneously.
It is possible to detect functional tumour perfusion using
the vascular marker Hoechst 33342. One possible disadvan-
tage of this method is that a high concentration of Hoechst
has vasoactive properties in the RIF-1 tumour (van Geel,
unpublished results) and in the murine SCCVII tumour
(Trotter et al., 1990). For this study we used Hoechst in a
fairly high concentration of 30 mg kg-'. Pilot studies
indicated that this concentration provides sufficient fluores-
cence intensity in tumour tissue sections to allow accurate
counting using the image analysis system as used in this
study. Hoechst is unlikely to have had a worked influence on
the results of this image analysis study, however, since
animals were sacrificed within 1 min of administration.
Chaplin and Acker (1987) have previously demonstrated
that mean tumour cell fluorescence increased linearly as a
function of injected dose of Hoechst (3-30 mg kg-'),
indicating that large doses of Hoechst, although vasoactive,
do not cause immediate decreases in blood flow and staining.
The good correlation we saw between tumour perfusion
estimated from the image analysis of perfused vessels stained
by Hoechst and 86Rb extraction (separate studies) also
suggests that Hoechst-induced vasoconstriction was not a
serious problem in these studies.
In our study the mean relative vascular area was
approximately homogeneously distributed in a 5 mm un-
treated RIF-1 tumour. However, the data on tumour
perfusion indicate that the number of vessels per unit area
is not the only determining factor for tissue perfusion, since
many vessels may not be functional. It is not clear whether
the vessels in non-perfused areas identified in our studies were
permanently or temporarily non functional.
Untreated RIF-1 tumours (5 mm) are free of evident
necrosis and anti-theophylline staining revealed a low (<4%)
level of hypoxia. The precision with which NITP detects
small proportions of cells with intermediate levels of oxygen
is limited by non-specific background staining. When NITP is
injected before illumination (as in the experiments reported
here), chronic and acute hypoxic regions are stained. The
necrotic areas lack the ability to metabolise NITP. If NITP is
given after illumination, drug access is likely to be inhibited
for high light doses (> 100 J cm-'), which cause a rapid and
pronounced decrease in perfusion (van Geel et al., 1994).
Separate studies (data not shown) confirmed that this was,
indeed, the case, since NITP given immediately after
illumination only resulted in hypoxic staining after low light
doses. Protocols giving NITP before illumination are
therefore much more suitable for estimating treatment-
induced changes in hypoxic fraction. The data presented
here indicate that NITP is metabolised in PDT-treated
tumours at levels significantly higher than those measured
in untreated control tumours. A 15-fold increase of
metabolised drug was observed after PDT compared with
the untreated controls. Moore et al. (1993) only found a 1.5-
fold increase in hypoxic areas, detected with '23I-labelled
iodoazomycin arabinoside (IAZA, a nitroimidazole) in the rat
Dunning R3327 AR tumours after PDT. This difference can
probably be explained by the fact that the spontaneous
hypoxic fraction of this rat tumour is quite variable, with
mean values of 15-25%. It would therefore be difficult to
demonstrate very large increases in hypoxic fraction after
treatment. It is also possible that IAZA requires even lower
oxygen concentrations for its metabolism than does NITP, or
that the severity of PDT-induced hypoxia in the rat Dunning
tumour was less than in the RIF-1 tumour.
Occasionally, immunohistochemical staining of hypoxic
tumour areas was seen adjacent to the blood vessels. This
may represent an example of acute hypoxia in which the
blood flow has become temporarily disrupted at a time when
the drug was available in the tumour cells for bioreductive
metabolism. The duration of hypoxia was not measured in
this study, however previous experiments indicated that
blood flow was decreased for at least 24 h after PDT (van
Geel et al., 1994). The K value for radiobiological hypoxia is
0.4-0.5% (Begg et al., 1985; Hall, 1994). The dependence of
NITP metabolism on oxygen concentration is similar to
radiosensitivity, with a slightly lower K value of approxi-
mately 0.1% (Hodgkiss et al., 1991). This indicates that the
oxygen concentration in the tumour cells stained for bound
metabolites of NITP after PDT will probably be .0.1%. TheTumour hypoxia after PDTC L )
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degree of hypoxia required for bioreduction of NITP in the
tumour after PDT is similar to that required for other
bioreductive drugs. It is known that bioreduction of drugs
such as SR4233 and mitomycin C is strongly dependent on
oxygen levels with K values of approximately 5% or 0.05%
respectively (Marshall and Rauth, 1986; Koch, 1993). Thus,
PDT should decrease the oxygen concentration in the tumour
to below these levels to get an optimal effect from the
combination of PDT and bioreductive drugs.
The image analysis study reported here visualised and
quantified a significant decrease in vascular perfusion after
PDT with a concomitant increase in hypoxic areas in the
RIF-1 tumour. These results lend support to the proposals
for the combined use of PDT and bioreductive drugs to
exploit the PDT-induced hypoxia.
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